Our Vision In Action

Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies. 

Pipeline
Program DiscoveryPreclinicalPhase 1 Rights
Rights
Program SGR-1505 (MALT1)Relapsed / Resistant
Non-Hodgkin's Lymphoma
Phase 1
Schrödinger
Program SGR-2921 (CDC7)Hematological Cancers and
Solid Tumors
Preclinical
Schrödinger
Program Wee1Gynecological Cancers and
other Solid Tumors
Discovery
Schrödinger
Program 4 UndisclosedOncology
 
Discovery
Schrödinger
Program 2 UndisclosedImmunology
 
Discovery
Schrödinger
Program DiscoveryPreclinicalCLINICAL Rights
Rights
Program SOS1 / KRASKRAS-Driven Cancers
 
Discovery
Schrodinger and Bristol Myers Squibb
Program 2 UndisclosedOncology
Discovery
Schrodinger and Bristol Myers Squibb
Program UndisclosedImmunology
Discovery
Schrodinger and Bristol Myers Squibb
Program UndisclosedNeurology
Discovery
Schrodinger and Bristol Myers Squibb
Program Protein DegradersOncology, Immunology and
Neurology
Discovery
Schrodinger and Bristol Myers Squibb
Program UndisclosedOncology
Discovery
Schrodinger and Takeda
Rights
Program DNA Damage ResponseOncology
Discovery
Schrodinger and ZAI Lab
Rights
Rights

Collaborative Programs

We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.

COLLABORATOR
agios logoAgios
Ajax Therapeutics logoAjax Therapeutics
Bright Angel Therapeutics logoBright Angel Therapeutics
Lilly logoLilly
Morphic Therapeutics logoMorphic Therapeutics
Nimbus Therapeutics logoNimbus Therapeutics
Ono pharmeceutical logoOno pharmeceutical
Orexia Therapeutics logoOrexia Therapeutics
Sanofi logoSanofi
Structure Theraputics logoStructure Theraputics
Undisclosed
Collaborator Pipeline
Indication DiscoveryPRECLINICALPHASE 1PHASE 2PHASE 3FDA APPROVED COLLABORATOR
COLLABORATORINDICATION
agios logo
TIBSOVO*
FDA APPROVED
COLLABORATORINDICATION
agios logo
IDHIFA*
FDA APPROVED
COLLABORATORINDICATION
ajax therapeutics logo
Oncology
DISCOVERY
COLLABORATORINDICATION
ajax therapeutics logo
Oncology
DISCOVERY
COLLABORATORINDICATION
bright angel therapeutics logo
Antifungal
Discovery
COLLABORATORINDICATION
lilly logo
Oncology
Phase 1
COLLABORATORINDICATION
morphic therapeutics logo
Inflammatory Bowel Diseases
Phase 2
COLLABORATORINDICATION
morphic therapeutics logo
Fibrosis
Discovery
COLLABORATORINDICATION
morphic therapeutics logo
GI Indications
Discovery
COLLABORATORINDICATION
morphic therapeutics logo
Solid Tumors
Discovery
COLLABORATORINDICATION
morphic therapeutics logo
Undisclosed
Discovery
COLLABORATORINDICATION
nimbus therapeutics logo
Metabolic Diseases**
Phase 2
COLLABORATORINDICATION
nimbus therapeutics logo
Autoimmune and Inflammatory Diseases
Phase 2
COLLABORATORINDICATION
nimbus therapeutics logo
Immuno-oncology
Phase 1
COLLABORATORINDICATION
nimbus therapeutics logo
Autoimmune Disease and Cancer
Discovery
COLLABORATORINDICATION
nimbus therapeutics logo
Immuno-oncology
Discovery
COLLABORATORINDICATION
nimbus therapeutics logo
Undisclosed Targets
Discovery
COLLABORATORINDICATION
ono pharmeceutical logo
Undisclosed
Preclinical
COLLABORATORINDICATION
orexia therapeutics logo
Sleep Disorders
Discovery
COLLABORATORINDICATION
sanofi logo
Autoimmune Disease
Discovery
COLLABORATORINDICATION
sanofi logo
Oncology
Discovery
COLLABORATORINDICATION
structure logo
Pulmonary Arterial Hypertension
Phase 1
COLLABORATORINDICATION
shouti logo
Type 2 Diabetes / Obesity
Phase 1
COLLABORATORINDICATION
shouti logo
Idiopathic Pulmonary Fibrosis
Preclinical
COLLABORATORINDICATION
Undisclosed
Oncology
Phase 1

* Acquired by Servier

** Acquired by Gilead

Back To Top